Narcolepsy Type 1 patients may find hope in a new treatment, but is it a breakthrough or a controversial finding? A recent study reveals that oveporexton, an orexin-receptor 2 agonist, could be a game-changer for cognitive function in this patient group.
The Surprising Findings:
A secondary analysis of a phase 2 clinical trial (NCT05687903) has uncovered some intriguing results. Researchers found that oveporexton (TAK-861; Takeda Pharmaceuticals) significantly improved cognitive measures in adults with narcolepsy type 1. This includes enhanced attention, memory, and executive function, which are often affected by the condition.
But here's where it gets controversial: the initial phase 2 trial didn't focus on these cognitive benefits, even though they were recorded. The study, led by Dr. Gert Jan Lammers, aimed to explore the effects of oveporexton on cognitive improvements over an 8-week period. Participants were given oveporexton or a placebo, with doses varying from 0.5/0.5 mg to 7 mg/placebo.
The Cognitive Boost:
The results were eye-opening. After 8 weeks, the oveporexton groups showed remarkable improvements in attention, memory, and executive function. The Psychomotor Vigilance Task (PVT) revealed significant reductions in lapses, while the Continuous Paired Associate Learning (CPAL) test showed fewer errors. The One Back (ONB) test and International Digit Symbol Substitution Test–symbols (IDSST-s) further supported these findings, indicating enhanced cognitive performance.
And this is the part most people miss: the phase 2 trial, presented at the 2025 SLEEP Annual Meeting, initially focused on microsleeps. It found that oveporexton reduced microsleep rates and delayed their occurrence in NT1 patients. However, the cognitive improvements were not the primary focus, leaving a gap in our understanding of the drug's full potential.
The Phase 2 Trial Unveils More:
The phase 2 trial also showed that oveporexton significantly decreased microsleep rates prior to sleep onset, and prolonged the time until the first microsleep. These findings suggest that oveporexton may not only improve cognitive function but also reduce daytime sleepiness in NT1 patients.
So, is oveporexton the answer to cognitive challenges in narcolepsy type 1? The study authors believe it could be a promising treatment option. However, further research is needed to fully understand its effects and potential side effects. This controversial interpretation of the data sparks an important discussion: are we overlooking a potential breakthrough in narcolepsy treatment, or is caution warranted?
What do you think? Share your thoughts and join the conversation in the comments below.
